ArticleActa biomaterialia2026
Modeling Tenascin-C-rich metastatic tumor niches in engineered hydrogel biomaterials.
Article in Acta biomaterialia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The extracellular matrix (ECM) plays a pivotal role in shaping tumor behavior by providing biochemical and biophysical cues to cancer cells. Traditional 2D culture systems fail to recapitulate this complexity, and in vivo systems do not readily allow for interrogation of how individual ECM components influence tumor cell behavior. Here, we introduce a fully synthetic, tunable three-dimensional (3D) hydrogel that mimics a soft tissue tumor microenvironment (TME) to enable mechanistic studies of ECM-tumor interactions. The hydrogel features a proteolytically degradable poly(ethylene glycol) base network functionalized with integrin-binding peptides derived from ECM components collagen I and fibronectin. To model metastatic ECM and further tune the hydrogel, we incorporated a tenascin-C (TNC)-derived peptide. To study the impact of these tunable ECM parameters on cancer cell behavior, we encapsulated Ewing sarcoma (EwS) cells within the hydrogels. EwS is an aggressive bone and soft tissue tumor that commonly metastasizes to lung. Our studies demonstrated matrix-dependent growth and phenotypic variation of EwS cells. Specifically, the TNC peptide drove divergent tumor behaviors and induced cell state changes consistent with alterations induced by the native TNC protein. To facilitate downstream functional assays, the hydrogel incorporates sortase-degradable crosslinkers that enable non-perturbative recovery of encapsulated cells. This platform provides a reductionist and reproducible model for studying the ECM's role in cancer cell biology while addressing long-standing challenges in polymeric hydrogel degradation and cell retrieval. Collectively, this work establishes a biomaterials-based framework to dissect EwS tumor-ECM interactions in a controllable 3D microenvironment. STATEMENT OF SIGNIFICANCE: Engineered biomaterials to model Ewing sarcoma (EwS) have been previously employed to study metastasis to the bone. While important efforts, platforms to study EwS metastasis in lung - the most common site of metastasis - have not been developed. Here, we introduce a user-programmable biomaterial designed to mimic the environment of soft tissue metastases. The platform features several attributes: 1) it is mechanically matched to lung tissue; 2) it is readily functionalized with extracellular matrix protein-derived peptides (e.g., Tenascin-C); 3) encapsulated cells can be retrieved in a "biologically invisible" manner via sortase-mediated gel degradation, enabling expanded downstream analysis. This platform provides a powerful, reproducible tool to dissect tumor behavior and identify new targets for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.